Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
CNBC (www.cnbc.com), a Tier B publisher, filed this report on .
Signal breakdown
CurrentWire ranked this story 34.9 of 100 in the snapshot this page was rendered from.
- Freshness
- 8.9 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 4.5 of 10
- Velocity
- 0 of 5
Strongest signal: source authority, 14 of 20. How each signal is calculated.
Filed under Health · International · News.
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.